

Listing of the Claims:

Claims 1 through 15 (cancelled).

16. (Currently Amended) An isolated polypeptide comprising the an amino acid sequence of SEQ ID NO: 2 ~~or SEQ ID NO:3~~.
17. The isolated polypeptide of claim 16, wherein said polypeptide further comprises an affinity tag.
18. (New) The isolated polypeptide of claim 17, wherein said affinity tag is selected from the group consisting of: poly-histidine tract, protein A, glutathione S transferase, maltose-binding protein, and an immunoglobulin domain.
19. (New) An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:3.
20. (New) The isolated polypeptide of claim 19, wherein said polypeptide further comprises an affinity tag.
21. (New) The isolated polypeptide of claim 20, wherein said affinity tag is selected from the group consisting of: poly-histidine tract, protein A, glutathione S transferase, maltose-binding protein, and an immunoglobulin domain.
22. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence from residue 1 (Met) to residue 19 (Gly) of SEQ ID NO:2;
 - (b) an amino acid sequence from residue 20 (Thr) to residue 104 (Ala) of SEQ ID NO:2;
 - (c) an amino acid sequence from residue 105 (Ala) to residue 135 (Gln) of SEQ ID NO:2;
 - (d) an amino acid sequence from residue 136 (Ser) to residue 177 (Val) of SEQ ID NO:2; and
 - (e) an amino acid sequence from residue 178 (Pro) to residue 273 (Ser) of SEQ ID NO:2.

Response to the March 24, 2003 Office Action

23. (New) The isolated polypeptide of claim 22, wherein said polypeptide further comprises an affinity tag.
24. (New) The isolated polypeptide of claim 23, wherein said affinity tag is selected from the group consisting of: poly-histidine tract, protein A, glutathione S transferase, maltose-binding protein, and an immunoglobulin domain.
25. (New) An isolated polypeptide consisting of an amino acid sequence of SEQ ID NO: 2.
26. (New) An isolated polypeptide consisting of an amino acid sequence of SEQ ID NO: 3.
27. (New) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence from residue 1 (Met) to residue 19 (Gly) of SEQ ID NO:2;
 - (b) an amino acid sequence from residue 20 (Thr) to residue 104 (Ala) of SEQ ID NO:2;
 - (c) an amino acid sequence from residue 105 (Ala) to residue 135 (Gln) of SEQ ID NO:2;
 - (d) an amino acid sequence from residue 136 (Ser) to residue 177 (Val) of SEQ ID NO:2; and
 - (e) an amino acid sequence from residue 178 (Pro) to residue 273 (Ser) of SEQ ID NO:2.
28. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence from residue 1 (Thr) to residue 85 (Ala) of SEQ ID NO:3;
 - (b) an amino acid sequence from residue 86 (Ala) to residue 116 (Gln) of SEQ ID NO:3;
 - (c) an amino acid sequence from residue 117 (Ser) to residue 158 (Val) of SEQ ID NO:3; and
 - (d) an amino acid sequence from residue 159 (Pro) to residue 254 (Ser) of SEQ ID NO:3.

Response to the March 24, 2003 Office Action

29. (New) The isolated polypeptide of claim 28, wherein said polypeptide further comprises an affinity tag.
30. (New) The isolated polypeptide of claim 29, wherein said affinity tag is selected from the group consisting of: poly-histidine tract, protein A, glutathione S transferase, maltose-binding protein, and an immunoglobulin domain.
31. (New) A composition, comprising a pharmaceutically acceptable carrier and a polypeptide of claim 16.
32. (New) A composition, comprising a pharmaceutically acceptable carrier and a polypeptide of claim 19.
33. (New) A composition, comprising a pharmaceutically acceptable carrier and a polypeptide of claim 22.
34. (New) A composition, comprising a pharmaceutically acceptable carrier and a polypeptide of claim 28.